1. Jiangsu Hengrui Pharmaceuticals Co., Ltd. China’s first original PARP inhibitor fluzoparib approved for marketing [media release]. 17 Dec 2020. https://www.hrs.com.cn.
2. National Medical Products Administration. Drug Evaluation Center. The National Medical Products Administration approves the marketing of fluzoparib capsules [media release]. 14 Dec 2020. https://www.nmpa.gov.cn/directory/web/nmpa/yaopin/ypjgdt/20201214100312149.html.
3. Jiangsu Hengrui Pharmaceuticals Co., Ltd. AiRuiYi® (fluzoparib) capsules: Chinese prescribing information [Chinese]. Lianyungang: Jiangsu Hengrui Pharmaceuticals Co., Ltd.; 2020.
4. Wang L, Yang C, Xie C, et al. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci. 2019;110(3):1064–75.
5. Li N, Bu H, Liu J, et al. An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer. Clin Cancer Res. 2021. https://doi.org/10.1158/1078-0432.CCR-20-3546.